FLT3 and acute myeloid leukemia: In another trial enrolling 27 newly diagnosed FLT3-ITDmut AML patients who were not candidates for intensive chemotherapy, Sorafenib combined with 5-Azacytidine reported a 78% overall response rate (ORR), with a median duration of remission of 14.2 months and an acceptable safety profile [28].